Although pan-cancer analysis showed overexpression of VIM in most cancer types, its overall survival rate was promising, with 65.3 months of life expectancy in patients, thus making it an attractive diagnostic biomarker for aggressive stages of GBM. The gene discussed is VIM; the disease is cancer.